Ipilimumab
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Ipilimumab: From Metastatic Melanoma to Choroideremia
One-Sentence Summary
Ipilimumab is an immune checkpoint antibody (anti-CTLA-4) originally used to treat metastatic melanoma. The TxGNN model predicts it may be effective for choroideremia (a rare inherited retinal degeneration), but no clinical trials and no publications currently support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Metastatic melanoma |
| Predicted New Indication | Choroideremia |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the compiled data. Ipilimumab is known to block CTLA-4, which enhances T-cell priming and activation. This is the basis of its use in melanoma, where it helps the immune system attack tumour cells.
Choroideremia is a different kind of disease. It is an X-linked inherited retinal degeneration caused by loss of function of the CHM gene (REP1 protein). It is not driven by tumor immune evasion, so there is no plausible biological reason why CTLA-4 blockade would help. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Systemic checkpoint blockade can also cause immune-related eye adverse events such as uveitis. These would be undesirable in an already degenerating retina.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name |
|---|---|
| 02379384 | YERVOY |
Dosage form and approved indication text were not available for this licence.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Immunotherapy (anti-CTLA-4 monoclonal antibody), not a conventional cytotoxic agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Immune-related adverse events: liver function, thyroid function, and signs of colitis, dermatitis and ocular inflammation. Please also refer to the package insert. |
| Handling Protection | Please refer to the package insert and local institutional handling policies |
Safety Considerations
- Drug Interactions: 100 interactions were identified. The 20 listed in the compiled data include:
- Major: anticoagulants, including apixaban, betrixaban, bivalirudin, dalteparin, desirudin, edoxaban, argatroban and danaparoid.
- Moderate: corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone), metronidazole, tinidazole, naltrexone, rosuvastatin and simvastatin.
- Ocular risk: Immune-related eye inflammation, such as uveitis, is a recognised risk of checkpoint blockade. This is a particular concern in a retinal disease.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but there are no trials or publications for choroideremia. The disease mechanism (inherited loss of CHM function) has no plausible link to CTLA-4 blockade. Immune-related eye toxicity adds a safety concern.
To proceed, the following is needed:
- Mechanistic or preclinical evidence linking CTLA-4 blockade to retinal degeneration in choroideremia
- Package insert warnings and contraindications, particularly for ocular adverse events
- Detailed mechanism of action data
- Confirmation that the high score is not a TxGNN model (deep learning) artefact
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.